Clinical Trial

A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study will compare the transmissible levels of poliovirus type-2 detected in stool samples collected at the time of the nOPV2 challenge and subsequent timepoints in 3 groups of newborns receiving an nOPV2 dose at birth and primed with 3 doses of IPV (6 - 10 - 14 weeks of age).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-06.
Trial Details
NCT Number NCT07010822
Lead Sponsor Fidec Corporation
Collaborators: Bill and Melinda Gates Foundation
Conditions Poliomyelitis
Enrollment 740 participants
Start Date 2025-12-08
Primary Completion 2026-09-21 (estimated)
Study Completion 2026-09-21 (estimated)
Updated on ClinicalTrials.gov 2025-07-24